Honokiol, a Constituent of Oriental Medicinal Herb Magnolia Officinalis, Inhibits Growth of PC-3 Xenografts in Vivo in Association with Apoptosis Induction
Overview
Affiliations
Purpose: This study was undertaken to determine the efficacy of honokiol, a constituent of oriental medicinal herb Magnolia officinalis, against human prostate cancer cells in culture and in vivo.
Experimental Design: Honokiol-mediated apoptosis was assessed by analysis of cytoplasmic histone-associated DNA fragmentation. Knockdown of Bax and Bak proteins was achieved by transient transfection using siRNA. Honokiol was administered by oral gavage to male nude mice s.c. implanted with PC-3 cells. Tumor sections from control and honokiol-treated mice were examined for apoptotic bodies (terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay), proliferation index (proliferating cell nuclear antigen staining), and neovascularization (CD31 staining). Levels of Bcl-2 family proteins in cell lysates and tumor supernatants were determined by immunoblotting.
Results: Exposure of human prostate cancer cells (PC-3, LNCaP, and C4-2) to honokiol resulted in apoptotic DNA fragmentation in a concentration- and time-dependent manner irrespective of their androgen responsiveness or p53 status. Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels. Transient transfection of PC-3 cells with Bak- and Bax-targeted siRNAs and Bcl-xL plasmid conferred partial yet significant protection against honokiol-induced apoptosis. Oral gavage of 2 mg honokiol/mouse (thrice a week) significantly retarded growth of PC-3 xenografts without causing weight loss. Tumors from honokiol-treated mice exhibited markedly higher count of apoptotic bodies and reduced proliferation index and neovascularization compared with control tumors.
Conclusion: Our data suggest that honokiol, which is used in traditional oriental medicine for the treatment of various ailments, may be an attractive agent for treatment and/or prevention of human prostate cancers.
Rahman M, Akter K, Ahmed K, Maharub Hossain Fahim M, Aktary N, Park M Cancers (Basel). 2024; 16(16).
PMID: 39199550 PMC: 11352813. DOI: 10.3390/cancers16162777.
Fei Y, Zhang X, Wang X, Sun Y, He J, Liu X J Nat Med. 2023; 78(2):285-295.
PMID: 38082192 DOI: 10.1007/s11418-023-01757-z.
Zgorka G, Adamska-Szewczyk A, Baj T Molecules. 2023; 28(17).
PMID: 37687163 PMC: 10488917. DOI: 10.3390/molecules28176335.
Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies.
Hao Q, Wu Y, Vadgama J, Wang P Biomolecules. 2022; 12(9).
PMID: 36139145 PMC: 9496067. DOI: 10.3390/biom12091306.
Chen Y, Lin C, Su C, Yang W, Chuang C, Su S Biomedicines. 2021; 9(10).
PMID: 34680412 PMC: 8533260. DOI: 10.3390/biomedicines9101295.